Chemomab Therapeutics Ltd.
Chemomab Therapeutics is a clinical-stage biotechnology company based in Tel Aviv, Israel. It discovers and develops therapeutics for fibrotic and inflammatory diseases, with a focus on rare conditions. Its lead product candidate, nebokitug, is a humanized monoclonal antibody designed to bind and block the activity of CCL24, a protein involved in inflammation and fibrosis. Chemomab is developing nebokitug primarily for primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab has completed a Phase 2 study of nebokitug in PSC and is preparing a Phase 3 trial. Its SSc program is Phase 2-ready, but initiation of the study is suspended while the company focuses resources on PSC. The company has also studied nebokitug in liver fibrosis associated with metabolic dysfunction-associated steatohepatitis (MASH) and in other clinical research. Its business centers on developing drug candidates for potential regulatory approval.
No SEC Form 4 filings for $CMMB in the last 30 days.
See all $CMMB insider activity →Scipher Medicine Corporation disclosed a 10.4% stake in Chemomab Therapeutics, buying 932,203 ADSs for $1.1 million. The purchase supports their planned merger, expected to close in Q1 2027, with the combined company trading on Nasdaq as SCIP. Scipher used convertible note proceeds and working capital for the purchase.
Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.
Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger to combine in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker SCIP. The focus is advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial using Scipher’s PrismRA test. A $30M private placement supports operations into H2 2028; Phase 2 readout expected H1 2028. Valuation cited at $150M pre-merger.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CMMB (Chemomab Therapeutics Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CMMB coverage spans financial news, mergers & acquisitions and market movers.
Chemomab's share price may face short‑term pressure as the company takes on new financing and moves toward a U.S. incorporation.
Deal terms and ownership split create a near-term valuation and risk re-pricing for CMMB, with contingent value rights tied to nebokitug milestones.
Deal terms and ownership split create a near-term valuation and execution risk/reward for CMMB holders until closing in Q4 2026.
Momentum appears tied to Phase 3 readiness and progress toward strategic partnering rather than new trial results.
Small insider purchase may signal confidence but limited market impact.
AlphAI scores every news story that mentions CMMB with an AI model for sentiment and relevance, and aggregates insider trades from Chemomab Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Scipher Medicine Corporation disclosed a 10.4% stake in Chemomab Therapeutics, buying 932,203 ADSs for $1.1 million. The purchase supports their planned merger, expected to close in Q1 2027, with the combined company trading on Nasdaq as SCIP. Scipher used convertible note proceeds and working capital for the purchase.
Chemomab Therapeutics (CMMB) and Scipher Medicine agreed to merge, forming a Nasdaq-listed company trading as SCIP. The combined firm will advance nebokitug, an anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial. Chemomab holders expected to own ~32% and Scipher ~68%, with contingent value rights. About $30M new funding; cash expected to fund through H2 2028. Deal expected to close Q4 2026; CMMB down to $2.39 pre-market.
Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger to combine in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker SCIP. The focus is advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial using Scipher’s PrismRA test. A $30M private placement supports operations into H2 2028; Phase 2 readout expected H1 2028. Valuation cited at $150M pre-merger.
Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
Mor George Adi (Chief Executive Officer) purchased 9,804 shares of Chemomab Therapeutics Ltd. (CMMB) at an average of $2.07 ($2.05–$2.08) across 2 trades on 2026-05-29.
Chemomab Therapeutics Ltd. has announced its Annual General Meeting for April 28, 2026, where shareholders will vote on four key proposals. These proposals include the re-election of two Class II directors, the approval of a refreshed compensation policy, a significant increase in authorized share capital by 8 billion ordinary shares, and the re-appointment of KPMG International's Somekh Chaikin as independent auditors for 2026. The increase in authorized share capital aims to provide the company with flexibility for future financing, strategic transactions, and equity compensation needs.
This page provides news and market updates for Chemomab Therapeutics Ltd. (CMMB), a clinical-stage biotechnology company developing nebokitug for fibro-inflammatory diseases, particularly primary sclerosing cholangitis (PSC). It highlights the company's clinical trial results, regulatory milestones, financial updates, and investor outreach activities. Recent news focuses on positive Phase 2 SPRING trial data for nebokitug in PSC and progress towards Phase 3 trials and regulatory approval.
TEL AVIV, Israel, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Chemomab Therapeutics Ltd. ( NASDAQ:CMMB ) ( Chemomab ) , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, ...
PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
